Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
First received: November 11, 2011
Last updated: January 9, 2014
Last verified: January 2014
The purpose of this study is to evaluate the degree of beta-cell dysfunction among participants with type 2 diabetes and the association between beta-cell dysfunction and demographic, clinical, and treatment variables.
||Observational Model: Cohort
Time Perspective: Prospective
||Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes
Primary Outcome Measures:
- Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) At 4 Years [ Time Frame: 4 Years ] [ Designated as safety issue: No ]
HOMA % B was defined as 20 x fasting insulin (mU/L)/fasting glucose (mmol/L)-
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2013 (Final data collection date for primary outcome measure)
Participants receiving routine care under a diabetologist.
|Ages Eligible for Study:
||41 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Participants visiting a diabetologist as part of their routine care. Investigator's prescription is not influenced by the study: Investigator decides about what is the best treatment for any single participant independently of the study.
- Physician diagnosis of type 2 diabetes mellitus by American Diabetes Association (ADA) criteria
- Oral hypoglycemic drug therapy for ≥1 year
- Continuous care at the clinic (at least 2 visits) for at least one year
- Medical records completed with a minimum core data set
- Completed consent form
- Participation in a clinical trial in the previous 1 year
- Currently using insulin
- Type 1 diabetes
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
||Merck Sharp & Dohme Corp.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 11, 2011
||January 9, 2014
||Italy: The Italian Medicines Agency
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 20, 2014
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders